Santacruzamate A, a Potent and Selective Histone Deacetylase Inhibitor from the Panamanian Marine Cyanobacterium cf. Symploca sp.

Researchers discovered santacruzamate A, a potent and selective histone deacetylase (HDAC) inhibitor derived from a marine cyanobacterium collected in Coiba National Park, a UNESCO World Heritage Site off Panama's Pacific coast. This compound, structurally similar to suberoylanilide hydroxamic acid (SAHA), demonstrates picomolar-level inhibition of HDAC2 while sparing other Class II HDACs like HDAC4 and HDAC6. The study involved phylogenetic analysis confirming the cyanobacterium as a potential new genus, followed by chemical fractionation to isolate santacruzamate A. Synthetic analogs were also developed, including a hybrid molecule combining features of both compounds, to evaluate HDAC activity and specificity. This discovery highlights the therapeutic potential of marine-derived natural products in targeting specific HDAC isoforms for disease treatment.

Pavlik, C. M., Wong, C. Y. B., Ononye, S., Lopez, D. D., Engene, N., McPhail, K. L., Gerwick, W. H., & Balunas, M. J. (2013). Santacruzamate A, a Potent and Selective Histone Deacetylase Inhibitor from the Panamanian Marine Cyanobacterium cf. Symploca sp. Journal of Natural Products, 76(11), 2026–2033. https://doi.org/10.1021/np400198r